Search
Methoxy arachidonyl fluorophosphonate
go.drugbank.com/drugs/DB02465ExperimentalIt inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range. … Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.
Egg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
Mixtures: LIPOFUNDIN N EMULSION FOR INFUSION 20 %Sulfaisodimidine
go.drugbank.com/drugs/DB13283ExperimentalSulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been
Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase
go.drugbank.com/drugs/DB18681ExperimentalIt comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV. … Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy.
Iron isomaltoside 1000
go.drugbank.com/drugs/DB12208ApprovedInvestigationalWithdrawnIron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia.
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.
Gluconolactone
go.drugbank.com/drugs/DB04564ApprovedGluconolactone is a naturally-occurring food additive used as a sequestrant, an acidifier, or a curing, pickling, or leavening agent. It is a cyclic ester of D-gluconic acid.
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
SLV319
go.drugbank.com/drugs/DB05077ExperimentalSLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.